List view / Grid view
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
The researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible.
Discover how Catalent can help you achieve efficiencies and develop a robust, reproducible manufacturing plan for late-stage and commercial launch.
US researchers develop a dual-action cell therapy engineered to eliminate established tumours and train the immune system to eradicate primary tumour and prevent cancer’s recurrence.
In their study, researchers duped antibodies with a decoy to prevent rejection of transplanted cells.
Using flow cytometry, Dr Greg Delgoffe and Dr Paolo Vignali highlight that low oxygen environment of tumours can prompt exhausted T cells to suppress the immune system instead of combating cancer.
This article highlights five of the latest findings using cell and gene therapy techniques that could be used in the development or design of new therapies.
US researchers, using new machine learning techniques have developed a virtual molecular library of “words” that encode commands to kill cancer cells.
This application note discusses why CAR T-cell therapy is so exciting, notes some common hurdles in development and manufacturing and proposes ddPCR technology as a solution for some of these issues.
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
US researchers have shown that CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity.
This supplement focuses on how cell and gene therapy can target diseases such as cancer and reduce elevated lipoprotein(a).
